Disease Landscape and Forecast Insights
Comprehensive market intelligence and actionable insights help you optimize your long-term disease strategy
Coronavirus COVID-19 – Executive Insights – Nonhospitalized COVID-19 Patients Executive Insights
The treatment landscape for COVID-19 continues to evolve rapidly. Despite the availability of vaccines in the markets under study, ongoing research focuses on decreasing viral loads and improving…
Non-Small-Cell Lung Cancer – Unmet Need – Unmet Need – Metastatic Nonsquamous Non-Small-Cell Lung Cancer Without Driver Mutations (US/EU)
Metastatic non-small-cell lung cancer (NSCLC) is a highly segmented indication defined by tumor histology and mutational status. Metastatic nonsquamous NSCLC patients are routinely tested for the…
Chronic obstructive pulmonary disease | Treatment Algorithms: Claims Data Analysis | US | 2022
Long-acting beta2 agonist (LABA) / long-acting muscarinic antagonist (LAMA) fixed-dose combinations (FDCs) are gaining traction in the chronic obstructive pulmonary disease (COPD) market,…
Multiple Sclerosis – Unmet Need – Unmet Need – Relapsing Forms of Multiple Sclerosis (US/EU)
An increasing number of clinically unique immunomodulatory disease-modifying therapies (DMTs) are approved for the treatment of relapsing forms of multiple sclerosis (MS), the most prevalent form…
